| scholarly article | Q13442814 |
| P50 | author | Leo Gordon | Q40235097 |
| P2093 | author name string | Lin Sun | |
| Hossein Ardehali | |||
| Michael A Burke | |||
| Sathyamangla V Naga Prasad | |||
| Amareshwar T K Singh | |||
| Sheila Prachand | |||
| Tejaswitha Jairaj Naik | |||
| Elliot D Lieberman | |||
| P2860 | cites work | Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors | Q24310559 |
| Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis | Q24310597 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Cell signaling by receptor tyrosine kinases | Q27860474 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death | Q28363890 | ||
| Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy | Q28593656 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| The ErbB/HER receptor protein-tyrosine kinases and cancer | Q34322472 | ||
| Trastuzumab-associated cardiotoxicity | Q34867708 | ||
| ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium | Q37145440 | ||
| Cardioprotective role of the mitochondrial ATP-binding cassette protein 1. | Q37372493 | ||
| Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up | Q39228415 | ||
| Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells | Q40048205 | ||
| Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors | Q40330942 | ||
| Structure-function relationships for the EGF/TGF-alpha family of mitogens | Q40543660 | ||
| Neuregulins in development | Q40943947 | ||
| ErbB2 is essential in the prevention of dilated cardiomyopathy. | Q43976647 | ||
| Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy | Q45175895 | ||
| Myosin-Binding Protein C Phosphorylation, Myofibril Structure, and Contractile Function During Low-Flow Ischemia | Q61913986 | ||
| Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin | Q73110180 | ||
| Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes | Q79148148 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | reactive oxygen species | Q424361 |
| P304 | page(s) | 2080-2087 | |
| P577 | publication date | 2008-11-18 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways | |
| P478 | volume | 284 |
| Q37419777 | A CaPful of mechanisms regulating the mitochondrial permeability transition |
| Q34430965 | A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells. |
| Q34312113 | Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury |
| Q34062716 | Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway |
| Q90482919 | Administration of trastuzumab with heart irradiation induced acute cardiotoxicity in mice |
| Q51760757 | Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. |
| Q45374763 | Association between obesity and trastuzumab-related cardiac toxicity in elderly patients with breast cancer |
| Q35427876 | Breast cancer therapy and cardiovascular risk: focus on trastuzumab |
| Q36339397 | Can ErbB2 overexpression protect against doxorubicin cardiotoxicity? |
| Q30251498 | Cancer drug related cardiotoxicity during breast cancer treatment |
| Q36887091 | Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. |
| Q36957758 | Cardiac side effects of anticancer treatments: new mechanistic insights |
| Q33352155 | Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors |
| Q43737795 | Cardioprotective effect of zinc requires ErbB2 and Akt during hypoxia/reoxygenation |
| Q37823035 | Cardiotoxicity associated with targeting kinase pathways in cancer |
| Q41896006 | Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation |
| Q37784108 | Cell communications in the heart. |
| Q55222160 | Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib. |
| Q38859661 | Differential behaviors of trastuzumab-sensitive and -resistant SKBR3 cells treated with menadione reveal the involvement of Notch1/Akt/FOXO1 signaling elements |
| Q57072196 | Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer |
| Q37072265 | ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells |
| Q36339400 | ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity. |
| Q49373130 | ErbB2 promotes endothelial phenotype of human left ventricular epicardial highly proliferative cells (eHiPC). |
| Q48257610 | Factors for time to trastuzumab-induced cardiotoxicity in breast cancer patients |
| Q37705396 | HER2 as a target for breast cancer therapy. |
| Q92533204 | HER2+ breast cancer treatment and cardiotoxicity: monitoring and management |
| Q37085606 | Heme levels are increased in human failing hearts |
| Q28548522 | High Bak Expression Is Associated with a Favorable Prognosis in Breast Cancer and Sensitizes Breast Cancer Cells to Paclitaxel |
| Q39253982 | High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model |
| Q92052896 | Implications of Autophagy and Oxidative Stress in Trastuzumab-Mediated Cardiac Toxicities |
| Q41718114 | Kinase inhibitor screening using artificial neural networks and engineered cardiac biowires |
| Q48228423 | Letter to the editor: "Doxorubicin and ErbB2 overexpression: another piece in the mitochondrial jigsaw". |
| Q92989657 | Measuring and regulating oxygen levels in microphysiological systems: design, material, and sensor considerations |
| Q37421172 | Mitochondria and vascular pathology. |
| Q24632770 | Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury |
| Q36387554 | NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies. |
| Q53193638 | Neuregulin-1β promotes glucose uptake via PI3K/Akt in neonatal rat cardiomyocytes. |
| Q38112350 | Novel aspects of ROS signalling in heart failure |
| Q39061588 | Overexpression of HER-2/neu protein attenuates the oxidative systemic profile in women diagnosed with breast cancer. |
| Q46396418 | Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity |
| Q50146298 | Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production |
| Q33862425 | Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy |
| Q55266333 | Reactive oxygen species promote tubular injury in diabetic nephropathy: The role of the mitochondrial ros-txnip-nlrp3 biological axis. |
| Q57807470 | Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target |
| Q37617873 | Snf1-related kinase improves cardiac mitochondrial efficiency and decreases mitochondrial uncoupling. |
| Q51358718 | Syntheses, structures and anti-tumor activity of four new organotin(iv) carboxylates based on 2-thienylselenoacetic acid. |
| Q58617728 | Takotsubo Cardiomyopathy During Anti-HER2 Therapy for Metastatic Breast Cancer |
| Q21284978 | The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy |
| Q55274551 | The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling. |
| Q33595716 | The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure |
| Q37368662 | The growth factor receptor ERBB2 regulates mitochondrial activity on a signaling time scale |
| Q36630478 | The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics. |
| Q37626273 | The role of antioxidants in the era of cardio‑oncology |
| Q48325287 | Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy |
| Q92847557 | Translational issues for mitoprotective agents as adjunct to reperfusion therapy in patients with ST-segment elevation myocardial infarction |
| Q36038613 | Trastuzumab Induces an Immediate, Transient Volume Increase in Humans: A Randomised Placebo-Controlled Trial |
| Q37131070 | Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies? |
| Q35532125 | Trastuzumab-induced cardiac dysfunction: A 'dual-hit' |
| Q34092821 | {beta}1-Adrenergic receptor activation induces mouse cardiac myocyte death through both L-type calcium channel-dependent and -independent pathways |
Search more.